Utama › Karsinoma Epitel Ovari › Washington
Kajian klinikal Karsinoma Epitel Ovari di Washington
6 kajian untuk Karsinoma Epitel Ovari sedang mencari peserta di lokasi di Washington.
Bandar di Washington
Teks kajian rasmi (Bahasa Inggeris)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585, Spokane
Mengambil pesertaFasa 2
Umur 18 ke atas · Wanita · Dikemas kini 29 Sep 2026 · NCT06890338Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Providence Sacred Heart Medical Center & Children's Hospital, Spokane
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 15 Sep 2026 · NCT06915025AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Seattle
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 21 Jul 2026 · NCT07218809A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Fred Hutchinson Cancer Center, Seattle
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT06395519Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- The Swedish Hospital, Seattle
Mengambil pesertaKajian pemerhatian
Umur 30 ke atas · Wanita · Dikemas kini 16 Sep 2025 · NCT04794322A Study of NX-1607 in Adults With Advanced Malignancies
- Fred Hutchinson Cancer Center, Seattle
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2025 · NCT05107674Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.